An open-label, non-randomized, multicenter, two-stage, phase 2 study of S-1 in chemotherapy-naive patients with locally advanced or metastatic pancreatic cancer.
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 31 Aug 2018 Biomarkers information updated
- 24 Feb 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 24 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.